3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
20
Genitourinary
19
Breast
16
Gynecologic
10
Other
8
Other hematologic neoplasm
4
Lymphoid
4
Dermatologic
4
Thoracic
3
Plasma cell
3
CNS
3
Sarcoma
2
Other solid neoplasm
2
Head & Neck
2
NET
1
Myeloid
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
41
Everolimus
38
Magnetic Resonance Spectroscopy
18
Temozolomide
17
lanreotide
16
gallium Ga 68 dotatate
15
Octreotide
14
pembrolizumab
13
Nivolumab
13
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
surufatinib
9
pasireotide
9
Sunitinib
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Lutetium-177
8
Carboplatin
8
amino-acid, glucose, and electrolyte solution
6
Ipilimumab
6
Ga(III)-DOTATOC
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
copper dotatate CU-64
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Diet Therapy
×
NET
×
Clear all
NCT02481804
2024-05-06
DIVIT-pilot
University Medical Center Groningen
Phase NA
Completed
15 enrolled